Verici Dx reaches Thermo Fisher collaboration milestone

Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced a significant milestone achievement under its agreement with Thermo Fisher Scientific on Monday.

  • Verici DX
  • 01 July 2024 13:34:33
Verici Dx

Source: Sharecast

The AIM-traded firm said Thermo Fisher confirmed the successful transfer and completion of all activities related to the pre-transplant prognostic testing technology licensed from Verici Dx.

It said the technology transfer enabled Thermo Fisher Scientific to develop a laboratory-developed test (LDT) in its own laboratories.

The achievement triggered a milestone payment to Verici Dx, as outlined in the global licensing and commercialisation agreement announced on 15 November last year.

Verici said the milestone aligned with previously-disclosed expectations.

“I am delighted to announce this smooth transition between Verici Dx and Thermo Fisher Scientific,” said chief executive officer Sara Barrington.

“This collaboration brings together Verici Dx's innovative technology into Thermo Fisher's new CLIA laboratory in the US, which will ultimately benefit patients and the field of organ transplantation.”

At 1057 BST, shares in Verici Dx were up 8% at 6.75p.

Reporting by Josh White for Sharecast.com.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.